Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Merck's Boserolimab?
Boserolimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Non-Small Cell Lung Cancer. According...
Data Insights
Risk adjusted net present value: What is the current valuation of Merck's Boserolimab?
Boserolimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Squamous Non-Small Cell Lung Cancer....